MINI-REVIEW

Resistin – a mediator of obesity-associated insulin resistance or an innocent bystander?

Olavi Ukkola

Department of Internal Medicine and Biocenter Oulu, University of Oulu, Kajaanintie 50/PO Box 5000, FIN-90220 Oulu, Finland

(Correspondence should be addressed to Olavi Ukkola; Email: olavi.ukkola@oulu.fi)

Abstract

The objective of this review is to summarize the current evidence of a novel adipocytokine, resistin. Resistin is a novel peptide hormone that belongs to a family of tissue-specific resistin-like molecules originally named for its resistance to insulin. Although a seminal proposal by Steppan et al. suggested resistin to be a hormone that links obesity to diabetes, several studies have subsequently been published supporting the concept that insulin resistance and obesity are actually associated with a decreased resistin expression. Resistin expression is regulated by a variety of agents and hormones, including thiazolidinediones, insulin, tumor necrosis factor alpha and growth hormone. Studies about their role in the regulation of resistin expression are, however, inconsistent in many cases. Experiments in humans have shown no differences in resistin expression between normal, insulin-resistant or type 2 diabetic samples. However, some recent genetic studies have demonstrated an association between resistin and insulin resistance and obesity. In addition, regional variation in the expression of resistin mRNA and protein levels in humans is an interesting finding with the highest levels found in the abdominal depot. In conclusion, resistin is a fascinating new hormone for which a definite role in metabolism will be revealed in the near future.

Introduction

It has become clear that adipose tissue and free fatty acids are key regulators of insulin sensitivity. Ectopic fat storage has recently been hypothesized to be one of the links between adiposity and insulin resistance (1). Another aspect is the endocrinological role of adipose tissue – it is known to secrete a large number of proteins (2). Among them, resistin is a novel signalling molecule induced during adipogenesis (3). It was originally named for its resistance to insulin. Resistin circulates in the blood (3) and it is a peptide hormone that belongs to a family of tissue-specific resistin-like molecules (4). The resistin mRNA encodes a 114 amino acid polypeptide containing a 20 amino acid signal sequence (5). Resistin is expressed in white adipose tissue with the highest levels in female gonadal adipose tissue (5). The adipocyte specificity of resistin gene expression is thought to be caused by CCAAT/enhancer-binding protein alpha (C/EBPα) binding (6). C/EBPs are a family of transcription factors that, like the peroxisome proliferator-activated receptor (PPAR) system, have been shown to be important in the regulation of adipocyte differentiation (7).

In this review the current evidence for and against the role of resistin in metabolic abnormalities is briefly summarized. This overview emphasizes the fact that the fundamental role of resistin in animals and, particularly, in humans is still unclear even though the knowledge is expected to grow all the time.

The role of resistin in insulin resistance and obesity

Evidence for

The seminal proposal by Steppan et al. suggested resistin to be a hormone that links obesity to diabetes (3). Resistin serum levels were increased in obesity and resistin gene expression was induced during adipocyte differentiation (Fig. 1). In addition, administration of resistin impaired glucose tolerance and insulin action while neutralization of resistin reduced hyperglycemia in the mouse model of diet-induced insulin resistance (3). Anti-resistin IgG also potentiated insulin-stimulated glucose uptake supporting the notion that resistin’s effects on glucose metabolism were antagonistic to those of insulin. In line with these findings Kim et al. (8) reported that resistin’s mRNA levels were markedly increased during 3T3-L1 and primary pre-adipocyte differentiation into adipocytes. They also showed that resistin mRNA levels were low during fasting but increased markedly when fasted mice were refeed or after insulin administration. However, resistin
had an inhibitory effect on adipose conversion and was, therefore, speculated to be a feedback regulator of adipogenesis and a signal to restrict adipose tissue formation (8). Recently, another gene expression study demonstrated that adipose tissue increases expression of multiple genes, including resistin, at the onset of high-fat-diet-induced obesity in rats (9). Peroxisome proliferator-activated receptor gamma (PPARγ) induces adipocyte differentiation (10). Thiazolidinediones, such as rosiglitazone, are ligands for the nuclear receptor PPARγ and produce insulin sensitizing effects (11). Interestingly, rosiglitazone treatment has been shown to decrease resistin mRNA (6, 12, 13) and serum levels (3). Li et al. created a transcription factor that activated transcription of PPARγ-responsive genes in the absence of ligand by fusion of the potent viral transcriptional activator VP16 to PPARγ2 (VP16-PPARγ) (14). Resistin gene expression was reduced in VP16-PPARγ adipocytes treated with thiazolidinediones.

Regional variation in the expression of resistin has also been observed. Excessive adiposity, particularly abdominal adiposity, is undoubtedly one of the determining factors leading to the clustering of metabolic disturbances observed in the metabolic syndrome. A recent report suggests an increase in resistin mRNA expression in abdominal depots compared with thigh (15) providing one explanation for the increase in metabolic abnormalities in abdominal obesity. The same group has recently confirmed the increased expression of resistin in abdominal fat also at the protein level (16).

**Evidence against**

Way et al. were the first to demonstrate that experimental obesity in rodents is associated with severely defective resistin expression (17). Subsequently, several studies have been published supporting the concept that insulin resistance and obesity are actually associated with decreased resistin expression. For instance, an insulin-resistant rat model experienced suppressed gene expression of adipocyte resistin gene (18). Free fatty acids were found to suppress the expression of resistin gene in normal rat adipocytes. Beta-adrenergic stimulation, which activates lipolysis and free acid release inducing insulin resistance, has been found to decrease resistin gene expression in 3T3-L1 adipocytes (19). Insulin has been suggested as a major inhibitor of resistin production (13), which may explain the low resistin mRNA levels in insulin resistance. Also tumor necrosis factor alpha, elevated in obesity, inhibits resistin gene expression (20). In addition, the transgenic mice developing high-fat diet-induced obesity exhibited downregulated adipocyte resistin mRNA levels in isolated fat cells (21). Beta 3-adrenergic agonists, shown to have antidiabetic and antiobesity properties, have been reported to produce an increase in resistin gene expression in diet-induced obesity in animals (22).

Resistin gene expression did not seem to be involved in the etiology of insulin resistance in Fischer 344 rats that represent a good model for typical metabolic syndrome in humans (23).

Human studies do not provide evidence that resistin is a key player in the development of insulin resistance. Resistin expression in human fat and muscle cells in relation to insulin resistance was studied by Nagaev & Smith (24). The results suggested that resistin was not detectable at all in human muscle and fat cells. Furthermore, no differences were found between normal, insulin-resistant or type 2 diabetic samples. Similar results were found by Savage et al. (25). They did not detect resistin mRNA in adipocytes from a severely insulin-resistant subject. Although resistin mRNA levels were increased in morbidly obese humans in whole adipose tissue samples, they were very low in freshly isolated human adipocytes. Importantly, PPARγ agonists did not have an effect on mononuclear cell resistin expression (25), being in contrast to several studies in animals (3, 6, 12, 13). It should be pointed out, however, that Way et al. observed that PPARγ agonists actually stimulated adipose tissue resistin expression (17). In addition, Savage et al. (25) did not observe any correlation between body mass index and adipocyte resistin expression. Recently, the expression of the resistin gene in primary cultured human adipocytes and preadipocytes was studied by Janke et al. (26). They found higher expression of the resistin gene in human pre-adipocytes and the expression decreased during adipogenic differentiation to mature cells. In this study resistin gene expression was not related to insulin resistance.

**Regulators of resistin expression**

Figure 2 shows the factors that have been reported to regulate resistin gene expression. A number of hormones and agents affect resistin expression but the results are contradictory in some cases, that is the case in insulin’s effects on resistin expression. Thiazolidinediones decrease resistin expression in most studies. A recent study suggests that resistin expression is regulated by a variety of hormones (27). Interestingly, growth hormone seems to induce resistin gene expression in white adipose tissue in rats (28).

**Genetics of resistin**

The human resistin gene is located on chromosome 19p13.3 (3). Resistin is encoded by three exons. Systematic search for single nucleotide polymorphisms (SNP) in the resistin gene has yielded genetic variations in the non-coding but not coding region. Recently, three SNPs in the promoter, intron 2 and intron 3 regions were shown to be determinants of insulin sensitivity index in interaction with body mass index.
in a study conducted on individuals of Northern European ancestry in Utah (29). In another study two resistin promoter polymorphisms were associated with obesity among the French Canadian population (30). However, genetic variations at the resistin gene did not show any association with obesity or type 2 diabetes in Italian (31) or Japanese (32) populations.

**Conclusions**

Although the first report proposed resistin serum levels to be increased in the obese state, a number of later publications have demonstrated decreased resistin gene expression in obesity. The way resistin was measured and the differences between serum concentrations and mRNA and protein levels probably contribute to the inconsistency observed in these studies. However, this does not necessarily rule out
the possibility that resistin could still play a role in metabolic disorders. Some recent genetic studies have demonstrated an association between resistin and insulin resistance and obesity. In addition, regional variation in the expression of resistin mRNA and protein levels in humans is an interesting finding with the highest levels found in the abdominal depot. In conclusion, the role of resistin in human diseases and physiology remains elusive. However, the current evidence suggests it to be more an innocent bystander than a real player in metabolic disorders in humans. Now, the challenging task is to investigate the course of resistin expression during the development of insulin resistance. In addition, the genetic knockout of resistin is likely to reveal many of the phenotypic effects of resistin.

References


Received 9 July 2002
Accepted 15 July 2002